Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)

Inclusion Criteria: * Participant lives in Massachusetts, Connecticut, Florida, Maine, New Hampshire, New York, Rhode Island, Texas, Vermont, California, Michigan, Illinois, North Carolina, Virginia, Arizona, and Alabama. * Diagnosis of opioid use disorder prescribed a stable dose of buprenorphine (at least 4 weeks) * Less than 90 days of abstinence (from non-prescribed opioids or benzodiazepines, cocaine, or alcohol) OR OUD with a co-morbid anxiety or stress disorder (as evaluated by Computerized Adaptive Testing for Mental Health \[CAT-MH\] or PROMIS-ASF \> 55). * Able to use an electronic device with a videocamera to attend study groups and complete questionnaires. * Sufficient English fluency to understand procedures and questionnaires * Ability to provide informed consent. Exclusion Criteria: * Active psychosis * Bipolar I disorder history or severe level of mania on CAT-MH (\>71) * Acute suicidality or self-injurious behavior or severe level of suicidality on CAT-SS (\>71) * Cognitive inability as demonstrated by both the inability to complete an informed consent assessment AND complete the Montreal Cognitive Assessment Blind (MOCA BLIND) \<24 on two different days * Current participation in another experimental research study * Previous participation in an 8-week intensive Mindfulness-Based Intervention in past 3 years or participation in the MINDFUL-OBOT pilot study * Expected medical hospitalization in next 6 months * Expected incarceration in next 6 months * Subs…